Portuguese pharmaceutical group FHC will use its acquisition of Activo Health to build its African footprint, beginning with a push into South Africa’s sterile injectables market, senior executives said yesterday. The privately held group bought Activo Health from JSE-listed Afrocentric. FHC owns Laboratórios Basi, a drugmaker based in Mortágua, Portugal, which reported turnover of about €543m (roughly R10bn) in 2025.…
Tag: Adcock Ingram
-
Calls for Drug Company Nationalisation After Adcock Job Cuts
Calls for drug company nationalisation have been made by the General Industries Workers Union of South Africa (Giwusa). These calls follow plans by Adcock Ingram to retrench more than 240 workers. Giwusa president Mametlwe Sebei said South Africa’s pharmaceutical sector had lost about 2,500 direct jobs over the past 18 months. He noted that nine local manufacturing plants closed during…
-
Excessive Dialysis Product Pricing: Adcock Ingram Referred
South Africa’s Competition Commission has referred pharmaceutical manufacturer Adcock Ingram’s hospital division to the Competition Tribunal for prosecution over alleged excessive pricing of kidney dialysis products. The referral, announced on 3 June 2026, targets Adcock Ingram Critical Care (AICC) and covers pricing for peritoneal dialysis and continuous renal replacement therapy (CRRT) products between July 2019 and June 2024. The commission…
-
Adcock Ingram Delisting After Natco Acquisition
Pharmaceutical giant Adcock Ingram has confirmed its delisting from the Johannesburg Stock Exchange (JSE) on 11 November 2025. The move marks the end of its 17-year run as a public company. This follows the finalisation of a R4.2 billion acquisition scheme by the Indian-based Natco Pharma. The company announced that it had fulfilled or waived all conditions precedent for the…
-
Adcock Ingram Takeover Gets Green Light from Shareholders
Shareholders in Adcock Ingram, the renowned South African pharmaceutical company, have decisively approved a takeover offer from Indian drugmaker Natco Pharma. This paves the way for the company to delist from the Johannesburg Stock Exchange (JSE) after 16 years. At a general meeting last week, shareholders voted 98.66% of shares in favour of the offer. The deal will see Natco…
-
Adcock Ingram Reports Flat Profit Despite Winter Surge
Pharmaceutical giant Adcock Ingram has announced flat annual profits despite a significant recovery in the second half of its financial year. This was buoyed by strong demand for its popular over-the-counter winter medicines. In a landmark move, the maker of household staples like Panado and Corenza-C is also set to delist from the Johannesburg Stock Exchange (JSE). This follows a…
-
Pharma Giants Sidelined in R15.5bn HIV Drug Tender
The National Department of Health has awarded its latest three-year antiretroviral (ARV) tender, valued at R15.5 billion. This decision leaves several of South Africa’s largest domestic pharmaceutical manufacturers without a contract. The government’s procurement strategy sidelines pharma giants and sparks a fresh debate. This debate pits aggressive cost-saving measures against its stated goal of bolstering local industrial capacity. The tender…
-
Bidvest’s Role in Adcock Ingram Takeover Bid
In a striking case of corporate déjà vu, South African pharmaceutical firm Adcock Ingram is once again the subject of a foreign takeover bid. However, the script has been flipped. Bidvest, the conglomerate that positioned itself as the company’s patriotic saviour over a decade ago, is now orchestrating its sale to an overseas partner. This culminates in a patient power…
-
Adcock Ingram to Delist Amidst Corporate Changes
Adcock Ingram, the pharmaceutical giant behind household brands such as Panado and Corenza-C, could delist from the Johannesburg Stock Exchange (JSE). This follows a significant deal between its majority shareholder, Bidvest, and Indian drugmaker Natco Pharma. The news saw Adcock’s share price surge by 24%. Under the terms of the agreement, Indian-listed Natco Pharma will acquire a significant minority stake…
-
Adcock Ingram’s Lenbucod Blocked by Court Ruling
The Pretoria High Court has dealt pharmaceutical giant Adcock Ingram a significant blow, ordering the company to cease selling and distributing its new painkiller, Lenbucod. This ruling effectively blocks Adcock Ingram’s Lenbucod from the market. The court found that the name infringed upon rival Aspen Pharmaceuticals’ existing trademark, Mybucod. This legal skirmish between the two JSE-listed heavyweights highlights the increasing…
-
Adcock Ingram: A picture of resilience in a challenging market
Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered an impressive 16.2% compound annual…